Enfusion (ENFN) News Today $11.50 +0.15 (+1.28%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$11.53 +0.04 (+0.30%) As of 02/21/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Enfusion (NYSE:ENFN) Hits New 1-Year High - Here's What HappenedEnfusion (NYSE:ENFN) Sets New 1-Year High - Should You Buy?February 21 at 11:51 AM | marketbeat.comClearwater Analytics' Enfusion Infusion Offers Compelling Value Proposition, Analyst Upgrades StockFebruary 20 at 2:31 PM | benzinga.comEnfusion, Inc. (NYSE:ENFN) Sees Significant Increase in Short InterestEnfusion, Inc. (NYSE:ENFN - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,010,000 shares, a growth of 41.9% from the January 15th total of 711,700 shares. Based on an average trading volume of 797,400 shares, the days-to-cover ratio is currently 1.3 days. Approximately 2.4% of the shares of the stock are sold short.February 15, 2025 | marketbeat.comEnfusion, Inc. (ENFN): Among The Small–Cap Stocks Insiders Are Selling RecentlyFebruary 15, 2025 | msn.comClearwater Analytics Holdings Inc. (CWAN) Among Hot Tech Stocks to Buy Right NowFebruary 6, 2025 | msn.comEnfusion, Inc. (NYSE:ENFN) Given Average Rating of "Hold" by BrokeragesShares of Enfusion, Inc. (NYSE:ENFN - Get Free Report) have been assigned an average recommendation of "Hold" from the six brokerages that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and tFebruary 6, 2025 | marketbeat.comEnfusion, Inc. (NYSE:ENFN) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC trimmed its position in Enfusion, Inc. (NYSE:ENFN - Free Report) by 72.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,929 shares of the company's stockFebruary 6, 2025 | marketbeat.comEnfusion, Inc. (NYSE:ENFN) Sees Large Growth in Short InterestEnfusion, Inc. (NYSE:ENFN - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 711,700 shares, a growth of 27.9% from the December 31st total of 556,500 shares. Based on an average daily volume of 695,500 shares, the short-interest ratio is currently 1.0 days. Approximately 1.5% of the shares of the stock are short sold.February 1, 2025 | marketbeat.comEnfusion, Inc. (NYSE:ENFN) Shares Bought by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its stake in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 612.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 208,022 shares of the company's stock aJanuary 23, 2025 | marketbeat.comWilliam Blair downgrades Enfusion (ENFN) to a HoldJanuary 18, 2025 | markets.businessinsider.comEnfusion (NYSE:ENFN) Sees Unusually-High Trading Volume - Here's WhyEnfusion (NYSE:ENFN) Sees Unusually-High Trading Volume - Should You Buy?January 16, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of ShareholdersJanuary 16, 2025 | prnewswire.comEnfusion, Inc. (NYSE:ENFN) Director Sells $17,237.61 in StockJanuary 16, 2025 | insidertrades.comBarclays PLC Boosts Stake in Enfusion, Inc. (NYSE:ENFN)Barclays PLC lifted its position in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 251.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,039 shares of the company's stock afterJanuary 16, 2025 | marketbeat.comEnfusion, Inc. (NYSE:ENFN) Director Deirdre Somers Sells 1,637 SharesEnfusion, Inc. (NYSE:ENFN - Get Free Report) Director Deirdre Somers sold 1,637 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.53, for a total transaction of $17,237.61. Following the transaction, the director now owns 41,675 shares in the company, valued at $438,837.75. The trade was a 3.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.January 15, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and EDBL on Behalf of ShareholdersJanuary 15, 2025 | globenewswire.comEnfusion downgraded to Hold from Buy at StifelJanuary 14, 2025 | finance.yahoo.comWilliam Blair Downgrades Enfusion (ENFN)January 14, 2025 | msn.comEnfusion (ENFN) was downgraded to a Hold Rating at William BlairJanuary 14, 2025 | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Enfusion, Inc.January 13, 2025 | prnewswire.comENFN Investors Have the Opportunity to Join Investigation of Enfusion, Inc. With the Schall Law FirmJanuary 13, 2025 | businesswire.comEnfusion's (ENFN) Market Perform Rating Reaffirmed at William BlairWilliam Blair reissued a "market perform" rating on shares of Enfusion in a research note on Monday.January 13, 2025 | marketbeat.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Enfusion, Inc. - ENFNJanuary 13, 2025 | prnewswire.comEnfusion (NYSE:ENFN) Shares Gap Up - What's Next?Enfusion (NYSE:ENFN) Shares Gap Up - Here's WhyJanuary 13, 2025 | marketbeat.comClearwater Analytics to acquire Enfusion in $1.5 billion dealJanuary 13, 2025 | msn.comClearwater Analytics Buys Enfusion in $1.5 Bln DealJanuary 13, 2025 | marketwatch.comClearwater To Acquire Enfusion - Quick FactsJanuary 13, 2025 | markets.businessinsider.comENFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to ShareholdersJanuary 13, 2025 | tmcnet.comClearwater Analytics to buy Enfusion for $11.25 a shareJanuary 13, 2025 | msn.comEnfusion to Merge with Clearwater Analytics HoldingsJanuary 13, 2025 | tipranks.comClearwater Analytics to acquire Enfusion in $1.5 bln dealJanuary 13, 2025 | reuters.comClearwater Analytics to Acquire Enfusion for $1.5 Billion Expanding its Investment Management Platform with Front-to-Back CapabilitiesJanuary 13, 2025 | businesswire.comEnfusion, Inc. (NYSE:ENFN) Given Consensus Recommendation of "Reduce" by BrokeragesEnfusion, Inc. (NYSE:ENFN - Get Free Report) has earned an average recommendation of "Reduce" from the six analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two haveJanuary 12, 2025 | marketbeat.comEnfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan Sells 2,771 SharesJanuary 11, 2025 | insidertrades.comOleg Movchan Sells 2,771 Shares of Enfusion, Inc. (NYSE:ENFN) StockEnfusion, Inc. (NYSE:ENFN - Get Free Report) CEO Oleg Movchan sold 2,771 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares of the company's stock, valued at $5,335,491.26. This represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.January 10, 2025 | marketbeat.comInsider Selling: Enfusion, Inc. (NYSE:ENFN) CFO Sells 4,134 Shares of StockEnfusion, Inc. (NYSE:ENFN - Get Free Report) CFO Bradley Herring sold 4,134 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $41,877.42. Following the completion of the sale, the chief financial officer now directly owns 266,369 shares in the company, valued at approximately $2,698,317.97. This represents a 1.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.January 10, 2025 | marketbeat.comGeode Capital Management LLC Has $9.77 Million Stock Holdings in Enfusion, Inc. (NYSE:ENFN)Geode Capital Management LLC grew its stake in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 7.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,029,366 shares of the company's stock after purchasing an addiJanuary 2, 2025 | marketbeat.comEnfusion, Inc. (NYSE:ENFN) Stock Holdings Increased by Barclays PLCBarclays PLC boosted its holdings in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 251.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 86,039 shares of the company's stock after purchasing an addJanuary 1, 2025 | marketbeat.comEnfusion (NYSE:ENFN) Shares Down 1.9% - Time to Sell?Enfusion (NYSE:ENFN) Shares Down 1.9% - Here's What HappenedDecember 31, 2024 | marketbeat.comEnfusion (NYSE:ENFN) Trading 4.2% Higher - Should You Buy?Enfusion (NYSE:ENFN) Shares Up 4.2% - Here's WhyDecember 30, 2024 | marketbeat.comSell Alert: Bradley Herring Cashes Out $259K In Enfusion StockDecember 27, 2024 | benzinga.comEnfusion (NYSE:ENFN) Shares Gap Down After Insider SellingEnfusion (NYSE:ENFN) Shares Gap Down After Insider SellingDecember 27, 2024 | marketbeat.comInsider Selling: Enfusion, Inc. (NYSE:ENFN) CFO Sells 24,443 Shares of StockDecember 27, 2024 | insidertrades.comEnfusion, Inc. (NYSE:ENFN) CFO Sells $259,340.23 in StockEnfusion, Inc. (NYSE:ENFN - Get Free Report) CFO Bradley Herring sold 24,443 shares of the company's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $10.61, for a total value of $259,340.23. Following the completion of the sale, the chief financial officer now owns 270,503 shares in the company, valued at $2,870,036.83. The trade was a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.December 26, 2024 | marketbeat.comEnfusion: Revenue Growth Should Start To AccelerateDecember 24, 2024 | seekingalpha.comEnfusion (ENFN) Receives a Hold from Piper SandlerDecember 23, 2024 | markets.businessinsider.comEnfusion price target raised to $11.50 from $10 at Piper SandlerDecember 23, 2024 | markets.businessinsider.comEnfusion (NYSE:ENFN) Reaches New 12-Month High After Analyst UpgradeEnfusion (NYSE:ENFN) Sets New 1-Year High Following Analyst UpgradeDecember 23, 2024 | marketbeat.comPiper Sandler Issues Positive Forecast for Enfusion (NYSE:ENFN) Stock PricePiper Sandler lifted their price target on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday.December 23, 2024 | marketbeat.comEnfusion price target raised to $13 from $11 at StifelDecember 20, 2024 | markets.businessinsider.com Get Enfusion News Delivered to You Automatically Sign up to receive the latest news and ratings for ENFN and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Media Mentions By Week ENFN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENFN News Sentiment▼0.490.65▲Average Computer and Technology News Sentiment ENFN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENFN Articles This Week▼23▲ENFN Articles Average Week Get Enfusion News Delivered to You Automatically Sign up to receive the latest news and ratings for ENFN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZETA News QTWO News ASAN News KC News FRSH News BOX News VRNS News WK News SAIC News TENB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ENFN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enfusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
